Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
| ▸ | STAT1 | P42224 | 1/20 | 0.52 |
| ▸ | TOP1 | P11387 | 4/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | CYCS | P99999 | 3/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | TERT | O14746 | 3/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78729 | 0.98 | STAT3 (0.50) | STAT3STAT1TOP1ABCG2CYCS | |
| SCHEMBL13445769 | 0.92 | STAT3 (0.45) | STAT3STAT1TOP1ABCG2CYCS | |
| SCHEMBL2791753 | 0.92 | STAT3 (0.45) | STAT3STAT1TOP1ABCG2CYCS | |
| SCHEMBL2791756 | 0.92 | STAT3 (0.45) | STAT3STAT1TOP1ABCG2CYCS | |
| SCHEMBL79276 | 0.87 | TOP1 (0.47) | TOP1ABCG2CYCSENPP2TERT | |
| SCHEMBL14657500 | 0.87 | STAT3 (0.60) | STAT3STAT1TOP1ABCG2CYCS | |
| SCHEMBL93007 | 0.86 | STAT3 (0.56) | STAT3STAT1TOP1ABCG2CYCS | |
| SCHEMBL78903 | 0.86 | STAT3 (0.56) | STAT3STAT1TOP1ABCG2CYCS | |
| SCHEMBL26285585 | 0.85 | STAT3 (0.55) | STAT3STAT1TOP1ABCG2CYCS | |
| SCHEMBL31127550 | 0.85 | STAT3 (0.55) | STAT3STAT1TOP1ABCG2TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669359-B2 | Electrically conducting porphyrin and porphyrin-fullerene electropolymers | ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669359-B2 | Electrically conducting porphyrin and porphyrin-fullerene electropolymers | ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669359-B2 | Electrically conducting porphyrin and porphyrin-fullerene electropolymers | ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2014-03-11 | — | — | US | disclosed |
| US-20100065123-A1 | Electrically conducting porphyrin and porphyrin-fullerene electropolymers | UNITED STATES DEPARTMENT OF ENERGY | 2010-03-18 | — | — | US | disclosed |
| US-20100065123-A1 | Electrically conducting porphyrin and porphyrin-fullerene electropolymers | UNITED STATES DEPARTMENT OF ENERGY | 2010-03-18 | — | — | US | disclosed |
| US-20100065123-A1 | Electrically conducting porphyrin and porphyrin-fullerene electropolymers | UNITED STATES DEPARTMENT OF ENERGY | 2010-03-18 | — | — | US | disclosed |
| WO-2008109467-A1 | ELECTRICALLY CONDUCTING PORPHYRIN AND PORPHYRIN-FULLERENE ELECTROPOLYMERS | ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100065123-A1 | Electrically conducting porphyrin and porphyrin-fullerene electropolymers | HMBS, PPOX, SLC40A1 | STAT3 1810/4885STAT1 3390/4885TOP1 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.